Achondroplasia: TransCon CNP Treatment for Infants

We are investigating the safety and growth effects of weekly injections of TransCon CNP in infants with achondroplasia. This study aims to understand how the treatment may help with growth and development.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

TransCon CNP
C-type Natriuretic Peptide

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Johannes Kepler University Linz
University Clinic for Pediatrics
Linz, Austria
Rigshospitalet
Clinical Trial Unit for children and adolescents
Copenhagen, Denmark
New Children’s Hospital, Helskinki University Hospital
Clinical Trials Unit
Helsinki, Finland

Sponsor: Ascendis Pharma Growth Disorders A/S
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.